Targeting pediatric malignancies for T cell-mediated immune responses.

C. L. Mackall, Lee J. Helman

Research output: Contribution to journalArticle

Abstract

Successful immune targeting of malignancies hinges upon the ability to activate specific T-cell populations to recognize and attack tumor but spare normal vital tissues. Investigators in the field of tumor immunology are currently utilizing at least three distinct approaches toward this goal. In the first approach, molecular targets of cytolytic T cells which spontaneously develop in tumor-bearing patients have been identified and are subsequently used as immunogens in immunotherapy trials. Whereas this approach originally focused upon the identification of tumor antigens in the immune-responsive tumors malignant melanoma and renal cell carcinoma, it surprisingly led to the identification of a variety of molecules that are now known to be expressed in other common pediatric and adult tumors. In the second approach, tumor-specific molecules (eg, mutant p53 and chromosomal translocations) that have been identified in individual tumors during the study of neoplastic transformation are used as immunogens. Because chromosomal translocations are common in pediatric tumors, such targets may be of particular interest in pediatric oncology. In the third approach, immunization with whole tumor cell components is undertaken with the assumption that the most immunogenic molecules within the tumor will dominate the immune response induced. The benefits and limitations for each approach, particularly as it pertains to the development of immunotherapy for pediatric tumors, are discussed in this article.

Original languageEnglish (US)
Pages (from-to)539-546
Number of pages8
JournalCurrent Oncology Reports
Volume2
Issue number6
StatePublished - Nov 2000
Externally publishedYes

Fingerprint

Pediatrics
T-Lymphocytes
Neoplasms
Genetic Translocation
Immunotherapy
Neoplasm Antigens
Cellular Structures
Allergy and Immunology
Renal Cell Carcinoma
Melanoma
Immunization
Research Personnel
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Targeting pediatric malignancies for T cell-mediated immune responses. / Mackall, C. L.; Helman, Lee J.

In: Current Oncology Reports, Vol. 2, No. 6, 11.2000, p. 539-546.

Research output: Contribution to journalArticle

Mackall, CL & Helman, LJ 2000, 'Targeting pediatric malignancies for T cell-mediated immune responses.', Current Oncology Reports, vol. 2, no. 6, pp. 539-546.
Mackall, C. L. ; Helman, Lee J. / Targeting pediatric malignancies for T cell-mediated immune responses. In: Current Oncology Reports. 2000 ; Vol. 2, No. 6. pp. 539-546.
@article{8a8d3270adff4db984454dc35f3a623e,
title = "Targeting pediatric malignancies for T cell-mediated immune responses.",
abstract = "Successful immune targeting of malignancies hinges upon the ability to activate specific T-cell populations to recognize and attack tumor but spare normal vital tissues. Investigators in the field of tumor immunology are currently utilizing at least three distinct approaches toward this goal. In the first approach, molecular targets of cytolytic T cells which spontaneously develop in tumor-bearing patients have been identified and are subsequently used as immunogens in immunotherapy trials. Whereas this approach originally focused upon the identification of tumor antigens in the immune-responsive tumors malignant melanoma and renal cell carcinoma, it surprisingly led to the identification of a variety of molecules that are now known to be expressed in other common pediatric and adult tumors. In the second approach, tumor-specific molecules (eg, mutant p53 and chromosomal translocations) that have been identified in individual tumors during the study of neoplastic transformation are used as immunogens. Because chromosomal translocations are common in pediatric tumors, such targets may be of particular interest in pediatric oncology. In the third approach, immunization with whole tumor cell components is undertaken with the assumption that the most immunogenic molecules within the tumor will dominate the immune response induced. The benefits and limitations for each approach, particularly as it pertains to the development of immunotherapy for pediatric tumors, are discussed in this article.",
author = "Mackall, {C. L.} and Helman, {Lee J.}",
year = "2000",
month = "11",
language = "English (US)",
volume = "2",
pages = "539--546",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Targeting pediatric malignancies for T cell-mediated immune responses.

AU - Mackall, C. L.

AU - Helman, Lee J.

PY - 2000/11

Y1 - 2000/11

N2 - Successful immune targeting of malignancies hinges upon the ability to activate specific T-cell populations to recognize and attack tumor but spare normal vital tissues. Investigators in the field of tumor immunology are currently utilizing at least three distinct approaches toward this goal. In the first approach, molecular targets of cytolytic T cells which spontaneously develop in tumor-bearing patients have been identified and are subsequently used as immunogens in immunotherapy trials. Whereas this approach originally focused upon the identification of tumor antigens in the immune-responsive tumors malignant melanoma and renal cell carcinoma, it surprisingly led to the identification of a variety of molecules that are now known to be expressed in other common pediatric and adult tumors. In the second approach, tumor-specific molecules (eg, mutant p53 and chromosomal translocations) that have been identified in individual tumors during the study of neoplastic transformation are used as immunogens. Because chromosomal translocations are common in pediatric tumors, such targets may be of particular interest in pediatric oncology. In the third approach, immunization with whole tumor cell components is undertaken with the assumption that the most immunogenic molecules within the tumor will dominate the immune response induced. The benefits and limitations for each approach, particularly as it pertains to the development of immunotherapy for pediatric tumors, are discussed in this article.

AB - Successful immune targeting of malignancies hinges upon the ability to activate specific T-cell populations to recognize and attack tumor but spare normal vital tissues. Investigators in the field of tumor immunology are currently utilizing at least three distinct approaches toward this goal. In the first approach, molecular targets of cytolytic T cells which spontaneously develop in tumor-bearing patients have been identified and are subsequently used as immunogens in immunotherapy trials. Whereas this approach originally focused upon the identification of tumor antigens in the immune-responsive tumors malignant melanoma and renal cell carcinoma, it surprisingly led to the identification of a variety of molecules that are now known to be expressed in other common pediatric and adult tumors. In the second approach, tumor-specific molecules (eg, mutant p53 and chromosomal translocations) that have been identified in individual tumors during the study of neoplastic transformation are used as immunogens. Because chromosomal translocations are common in pediatric tumors, such targets may be of particular interest in pediatric oncology. In the third approach, immunization with whole tumor cell components is undertaken with the assumption that the most immunogenic molecules within the tumor will dominate the immune response induced. The benefits and limitations for each approach, particularly as it pertains to the development of immunotherapy for pediatric tumors, are discussed in this article.

UR - http://www.scopus.com/inward/record.url?scp=0034326589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034326589&partnerID=8YFLogxK

M3 - Article

C2 - 11122890

AN - SCOPUS:0034326589

VL - 2

SP - 539

EP - 546

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 6

ER -